Blog

US FDA Staff Flags Concerns on MDMA-Assisted PTSD Treatment

May 31 • 2 min read

Earlier today, staff from the U.S. health regulatory body expressed concerns regarding the interpretation of data from trials on the psychedelic drug MDMA for treating post-traumatic stress disorder (PTSD). These concerns emerged ahead of an upcoming meeting of the agency’s advisory panel. The comments have set the stage for in-depth discussions on the benefits and…

Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder

May 30 • 3 min read

Vancouver, British Columbia–(Newsfile Corp. – May 30, 2024) – In a significant stride towards transforming mental health care, Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) has proudly announced that its research site, Cedar Clinical Research (CCR), has been selected for Cybin’s Phase 3 pivotal multinational clinical trial of CYB003. Aimed at revolutionizing the…

BrightGreen’s Update from the CEO

May 30 • 6 min read

Dear BGXX Shareholders, I’m writing to you today to share an update on several developments for Bright Green Corporation (“Bright Green” or the “Company”) over the past few months. We’ve experienced massive shifts within the industry since the start of 2024 — shifts that have presented exciting growth opportunities for Bright Green. https://727fc598ee75e396ae4c1435ddcc2c74.safeframe.googlesyndication.com/safeframe/1-0-40/html/container.html I’ll begin…

Numinus Wellness Charts Path To Profitability While Strengthening Community Ties

May 30 • 4 min read

Vancouver, British Columbia–(Newsfile Corp. – May 30, 2024) – Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (“Numinus” or the “Company”), a leader in mental health care and in advancing evidence-based psychedelic-assisted therapies, announces a strategic blueprint aimed at fortifying its footprint across the United States. Through a comprehensive cost optimization initiative, Numinus is poised to strengthen its already established…

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 30 • 6 min read

NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543